6,391
Views
10
CrossRef citations to date
0
Altmetric
Supplement: introducing oral semaglutide and the PIONEER program to primary care

Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy

ORCID Icon & ORCID Icon
Pages 26-36 | Received 01 Jun 2020, Accepted 16 Jul 2020, Published online: 08 Sep 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Stephen A. Brunton, Ofri Mosenzon & Eugene E. Wright Jr. (2020) Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?. Postgraduate Medicine 132:sup2, pages 48-60.
Read now

Articles from other publishers (8)

Jaianny Chaves Braga, Laura Alves de Aguiar Glória Barbosa, Samyra Giarola Cecílio & Larissa Mirelle de Oliveira Pereira. (2024) SIBUTRAMINA E LIRAGLUTIDA NA TERAPÊUTICA DA OBESIDADE. Revista Contemporânea 4:4, pages e4034.
Crossref
Tanya Saxena, Claire Sie, Kristine Lin, Daisy Ye, Katayoun Saatchi & Urs O. Häfeli. (2022) Potential of Nuclear Imaging Techniques to Study the Oral Delivery of Peptides. Pharmaceutics 14:12, pages 2809.
Crossref
Mohamed Sayed Zaazouee, Aboalmagd Hamdallah, Sara Kamel Helmy, Elfatih A. Hasabo, Ahmed Kamal Sayed, Mohamed Ibrahim Gbreel, Aya Abd Elmegeed, Hala Aladwan, Alaa Ahmed Elshanbary, Walid Abdel-Aziz, Israa Mohamed Elshahawy, Shehab Rabie, Sherouk Elkady, Ahmed Said Ali, Khaled Mohamed Ragab & Anas Zakarya Nourelden. (2022) Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:6, pages 102511.
Crossref
Zhaotong Cong, Qingtong Zhou, Yang Li, Li-Nan Chen, Zi-Chen Zhang, Anyi Liang, Qing Liu, Xiaoyan Wu, Antao Dai, Tian Xia, Wei Wu, Yan Zhang, Dehua Yang & Ming-Wei Wang. (2022) Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24. Proceedings of the National Academy of Sciences 119:20.
Crossref
Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, Anna-Sophie Thein, Jens Rovelt, Barbara Cvenkel, Pete A. Williams, Augusto Azuara-Blanco & Miriam Kolko. (2022) Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?. Frontiers in Neuroscience 16.
Crossref
Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Debbie Hicks, Pam Brown, Zaheer Yousef, Umesh Dashora, Adie Viljoen, Hannah Beba & W. David Strain. (2022) Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Therapy 13:2, pages 225-240.
Crossref
Zhaotong Cong, Li-Nan Chen, Honglei Ma, Qingtong Zhou, Xinyu Zou, Chenyu Ye, Antao Dai, Qing Liu, Wei Huang, Xianqiang Sun, Xi Wang, Peiyu Xu, Lihua Zhao, Tian Xia, Wenge Zhong, Dehua Yang, H. Eric Xu, Yan Zhang & Ming-Wei Wang. (2021) Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor. Nature Communications 12:1.
Crossref
Hans-Rudolf Berthoud, Vance L. Albaugh & Winfried L. Neuhuber. (2021) Gut-brain communication and obesity: understanding functions of the vagus nerve. Journal of Clinical Investigation 131:10.
Crossref